Lacrinorm

Carbomer, the active ingredient in Lacrinorm, is an ophthalmic excipient presented as a gel matrix for ocular use. It acts as a viscosity enhancer, forming a gel that increases the residence time of eye drops, thereby improving drug delivery for patients requiring sustained ocular therapy.

GNH USA supplies Lacrinorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant products to a global network of healthcare providers.

Lacrinorm, containing carbomer, is employed as a viscosity enhancer in ophthalmic formulations. - Ocular lubrication: prolongs tear film stability and enhances comfort in dry eye patients. - Post‑operative eye care: maintains therapeutic drug levels on the ocular surface after surgery. - Chronic ocular disease therapy: improves residence time of active agents in glaucoma or allergy eye drops.

Adverse reactions may occur with ocular administration of carbomer‑based products.

Common Side Effects: - Transient ocular irritation: mild stinging or burning upon instillation. - Temporary blurred vision: visual disturbance that resolves within minutes. - Mild conjunctival redness: slight redness without pain.

Serious or Rare Side Effects: - Allergic reaction: swelling, itching, or rash requiring discontinuation. - Corneal edema: swelling of the cornea leading to vision changes. - Severe ocular inflammation: uveitis or keratitis requiring medical attention.

When using Lacrinorm, consider the following precautions: - Patient assessment: evaluate ocular surface condition before use. - Allergy screening: check for known carbomer sensitivity. - Concurrent eye medications: avoid mixing with incompatible formulations. - Contact lens wearers: remove lenses before instillation. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct light.

Potential interactions with other ophthalmic products should be monitored.

Major Interactions (Avoid): - Incompatible ophthalmic gels: co‑administration may alter viscosity and drug release. - Preservative‑containing drops: may cause precipitation of the gel matrix.

Moderate Interactions (Monitor Closely): - Contact lens solutions: may affect gel stability. - Topical antibiotics: monitor for reduced efficacy. - Systemic medications: generally none, but observe for unexpected ocular effects.